Shanghai, China/Germantown, USA, June 14, 2022 -- Zencore Biologics today announced that it has entered into a Global Strategic Marketing Collaboration Agreement (SCA) with Amador Bioscience, with plans to jointly promote the various lines of services offered by both companies, to enable the One-Stop-Shop service selections for our biotech and pharmaceutical customers around the world. The initial stage of the joint marketing promotion will be carried out in China, United States and the European Union, where both companies have strong presence.
Zencore Biologics today announced that it has entered a Global Strategic Marketing Collaboration Agreement (SCA) Zencore Biologics and Amador Bioscience signed Global Strategic Marketing Collaboration Agreement (SCA)
Ms Chen, Xiaomin (left), COO of Amador Bioscience Dr. Hao, Weidong(right), CSO of Zencore Biologics
Dr Weidong Hao, CSO and SVP of Zencore Biologics, stated “we value greatly the strategic cooperation with Amador Biosciences. Zencore will work closely with Amador Biosciences in serving our clients worldwide. The strategic collaboration will enable our clients to take advantage of the complementary service offering from both Zencore Biologics and Amador Biosciences. Our expertise in drug development, commercial production, and clinical services will contribute to the success of our clients."
Ms. Xiaomin Chen, COO of Amador Bioscience, stated, "Amador Bioscience is committed to promoting the success of innovative drug development worldwide. Amador Bioscience and Zencore Biologics identify with each other's service and philosophy and appreciate each other's strengths. I am confident that the collaboration between the two companies will create a different kind of spark and contribute to the global success of more innovative drugs."